Search 33,000+ CME courses
Back

StatPearls, LLC

  • COVID-19
  • Ritonavir
  • Severe Acute Respiratory Syndrome

Nirmatrelvir-Ritonavir

Nirmatrelvir/ritonavir also referred to as ritonavir-boosted nirmatrelvir, is an oral combination medication used to treat coronavirus disease 2019 (COVID-19). It consists of nirmatrelvir, a protease inhibitor targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease, and ritonavir, a cytochrome P450 (CYP) 3A inhibitor. Nirmatrelvir/ritonavir was authorized for emergency use on December 22, 2021. It is currently one of the highly-effective oral antiviral medications available to treat COVID-19. This activity reviews the medication s indications and contraindications. It also reviews the mechanism of action, administration, monitoring, adverse effects, toxicity, and other elements related to treating patients with COVID-19. Information in this activity is pertinent to all members of the interprofessional healthcare team, including physicians, pharmacists, nurses, and other health professionals, who manage the care of patients with COVID-19.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1.5 creditsAAPA Category 1 Credit™Up to 1.5 creditsAMA PRA Category 1 Credit™Up to 1.5 creditsNursingUp to 1.5 creditsPharmacyUp to 1.5 credits

MOC types

ABS — Accredited CMEUp to 1.5 pointsABPATH — Lifelong LearningUp to 1.5 pointsABA — Lifelong LearningUp to 1.5 pointsABTS — Accredited CMEUp to 1.5 pointsABIM — Medical KnowledgeUp to 1.5 pointsABS — Self-AssessmentUp to 1.5 pointsABP — Lifelong Learning and Self-AssessmentUp to 1.5 pointsABTS — Self-AssessmentUp to 1.5 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 8 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1.5 credits
  • MOC · Up to 1.5 points
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left

More from StatPearls, LLC

See all

This provider’s courses closest to this one